Spots Global Cancer Trial Database for Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Official Title: NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-positive Locally Advanced Breast Cancer Patients
Study ID: NCT04126525
Conditions
Interventions
Study Description
Brief Summary: This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Renji Hospital, Shanghai, , China
Contact Details
Name: Jinsong Lu
Affiliation: RenJi Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
